Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (428)	1/17/1999 4:51:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

David: Certainly not puffery. They've been working on PEG forever. They used to champion the induction of tolerance and avoidance of immune responses using PEGylation, based on the work of a guy who IMO was only telling part of the story. I therefore didn't like them. However, they have worked the half-life issue consistently and it appears to be validated by work with epo variants by AMGN. That's about all the help I can be. What else are they doing? Not certain that they fit this thread at a price:book of 22, but.... what the heck. Thanks. Rick